🚨Trade Alert 🚨 TLSA

TLSA’s anticipated “wonder drug” could be revolutionary in the fight against Alzheimer’s Disease. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ TLSA’s anticipated “wonder drug” could be revolutionary in the fight against Alzheimer’s Disease. Greetings All, The biotech arena is home to all kinds of companies that are working on drug candidates to treat various conditions. Alzheimer’s disease is one of those conditions. It is a long, intractable illness that many giants are scrambling to vanquish or treat. This brings attention to an under-the-radar NASDAQ company trading at PENNIES, that may have a wonder drug that could be a game-changer in the fight against Alzheimer’s! Hurry and add Tiziana Life Sciences Ltd. (NASDAQ: TLSA) to your radar. []( TLSA is on a mission to bring breakthrough therapies to patients with the aim of treating Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, and other CNS indications. Not long ago the company was given the green light to investigate the potential of its drug candidate Foralumab to treat Alzheimer’s disease. This was a significant milestone for the company as well as for treatment for the disease at large.Recently TLSA announced the publication of a new study into the potential use of its Foralumab nasal spray as a treatment. The study was published in the Proceedings of the National Academy of Science (PNAS) journal and demonstrated significant improvements in Alzheimer ’s-related factors independent of amyloid beta and tau protein. Why is this significant?While current FDA-approved drugs target amyloid beta and tau protein, TLSA’s drug candidate takes a unique approach by resetting activated microglia in the brain to a baseline state. TLSA’s novel approach offers hope for Alzheimer’s patients around the world.You can read more about the study [HERE]( comes as no surprise that BULLISH ratings are piling up for the stock right now. Both [NASDAQ.com]( and [Investing.com]( have a “STRONG BUY” rating.Additionally, there is a [$3.00 price target!]( This price target implies possible upside of over 300%!!The biotech sector is filled with promising companies. Investors hunt high and low for those in the space that are trending and/or have exciting developments.TLSA has such developments…but first, more about the company’s wonder drug…Tiziana’s lead candidate, intranasal foralumab has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.What is Foralumab?Foralumab is the world’s only fully human, anti-CD3 mAb in clinical development!How important is anti-CD3 mAb? Well, it was recently announced in March that Provention Bio is being [acquired by Sanofi]( for $2.9 billion for the company's humanized anti-CD3 monoclonal antibody drug, teplizumab…Foralumab is gaining recognition across the scientific community with features in medical media that include Pharmacy Times. It was recently highlighted positively in a Forbes article that can be read here: [ The exciting potential for this treatment was also recently picked up in an article from the premier scientific journal, Proceedings of the National Academy of Sciences (PNAS). [PNAS]( reported on a recent trial where the treatment reduced inflammation in patients with both COVID-19 and MS patients. Clinical Trials…. TLSA has recently completed two Phase 1 clinical trials: one for progressive MS indication with nasal administration and the other for Crohn’s disease indication, with enteric-coated capsules administered orally.The company has also completed a Phase 2 trial treating mild to moderate non-hospitalized COVID-19 patients in Brazil with intranasal foralumab with positive results.Currently, six secondary progressive MS patients are being treated at Brigham and Women’s Hospital, Boston MA, with intranasal foralumab under Expanded Access INDs with signs of clinical benefit. EA1 has completed Twenty months of treatment and the EA2 has completed Thirteen months. Foralumab has demonstrated ability to activate regulatory T cells that systemically circulate to elicit targeted immunomodulation providing therapeutic benefit to patients.TLSA has submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases.The patent application covers inventions related to improving CAR-T expansion and/or survival. Foralumab administered alone or co-administered in combination with co-stimulatory molecules, such as an anti-IL-6 receptor monoclonal antibody, an anti-CD28 monoclonal antibody or specific inhibitors of signaling pathways of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), or mammalian target to improve success of CAR-T therapy.Late-stage Multiple Sclerosis…TLSA is focusing its research on foralumab's potential for treating late-stage MS.In late September, the company announced that it had held an [Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital]( a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, six to ten new clinical trial sites will be recruited.“As planned for this quarter, we are on track and have begun site initiation visits so patient enrollment begins in this critical clinical trial. Advancing our lead anti-CD3 therapeutic, foralumab, in na-SPMS into Phase 2a will enable Tiziana to define novel endpoints, such as PET imaging, a similar target endpoint in our Expanded Access program (EAP),” said Matthew W. Davis, M.D., RPh, Chief Operating Officer and Chief Medical Officer of TLSA.Five out of six patients in the company's open-label EAP have improved by qualitative analysis in their PET scans (3 months of treatment) compared to baseline. Phase 2a na-SPMS study assesses the same outcome measure, but now, and for the first time for this novel therapeutic, in a double-blind, randomized placebo control, a multi-center trial is now underway.The Alzheimer’s opportunity…The most exciting news as of late however is TLSA’s potential to treat Alzheimer’s disease…Watch this YouTube video about the company’s Alzheimer's Disease treatment being validated in a new study: [ the ultimate impact of Foralumab in the fight against Alzheimer's remains uncertain pending Phase II data, the promising results suggest it could become a vital player in the quest for effective treatments. Matthew W. Davis, M.D., RPh, Chief Operating Officer and Chief Medical Officer of TLSA acknowledges the vast potential of the Alzheimer's market, which remains underserved. He emphasizes the unique approach of Foralumab as the only fully human anti-CD3, which sets it apart from existing treatments! This is very exciting stuff. Keep an eye on TLSA’s news for more developments on this! In Summary… Biotech is a red-hot industry with diligent eyes on the arena watching out for the next big thing. The potential for substantial returns makes companies in the space perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success and TLSA looks like one of them! The company is aiming to bring to market a unique drug candidate that could significantly help millions of people. Insider ownership stands at a staggering 43% indicating that the company’s team has complete faith in their lead candidate Foralumab turning it into the next biotech darling! There could be phenomenal growth potential here as Wall Street continues to learn about TLSA’s lead drug candidate. There’s only one reason why insiders would be loading up and that’s because they believe their company is headed higher… The cogs are in motion and Tiziana Life Sciences Ltd. (NASDAQ: TLSA) could be heading toward an FDA green light in the future. Now is the time to have the company high on your radar! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in TLSA. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding TLSA with a start date of 10/13/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]